Renal Cell Carcinoma
10 competing products in clinical development for Renal Cell Carcinoma.
Pipeline by Phase
Phase 14
Phase 24
Phase 32
All Products (10)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Lenvatinib + Everolimus + Pembrolizumab + Sunitinib | Eisai | Phase 3 | Active | 44 |
| Nivolumab + Cabozantinib + Sunitinib + Ipilimumab | Ono Pharmaceutical | Phase 3 | Active | 44 |
| CP-461 | Astellas Pharma | Phase 2 | Completed | 35 |
| lenvatinib + everolimus | Eisai | Phase 2 | Completed | 35 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | Completed | 35 |
| DS-6000a + DS-6000a | Daiichi Sankyo | Phase 1 | Active | 33 |
| AGS-16M8F | Astellas Pharma | Phase 1 | Completed | 29 |
| Lenvatinib + Everolimus | Eisai | Phase 1 | Completed | 29 |
| Nivolumab + Pazopanib + Sunitinib + Ipilimumab | Ono Pharmaceutical | Phase 1 | Completed | 29 |
| Decitabine + Interferon Alfa-2b | Eisai | Phase 2 | Terminated | 27 |